Matthew Galsky

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.

The role of taxanes in the management of bladder cancer.

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Violaceous exanthem as a manifestation of metastatic prostate cancer in skin.

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Problems with the randomized discontinuation design.

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.

Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.

High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care?

Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.

Outcomes and prognosis in advanced renal cell carcinoma.

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Germ-cell tumors.

Novel agents for muscle-invasive and advanced urothelial cancer.

Current optimal chemotherapy for advanced urothelial cancer.

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.

Trial design for metastatic castration-resistant prostate cancer.

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.

Patient selection for phase II trials.

Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis.

The integration of chemotherapy and surgery for bladder cancer.

Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer.

Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.

Bladder cancer: advances in treatment and research.

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.

First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?

Cabazitaxel.

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

Bladder cancer: current management and opportunities for a personalized approach.

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.

Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.

Role of American Society of Clinical Oncology in low- and middle-income countries.

Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.

Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.

Editorial comment.

Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status.

Overcoming castration resistance in prostate cancer.

Novel molecular targets for the therapy of urothelial carcinoma.

The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.

Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.

Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.

The emerging role of circulating tumor cell detection in genitourinary cancer.

Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.

Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.

Trends in the use of cytoreductive nephrectomy in the United States.

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.

Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?

Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.

Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.

Antiangiogenic treatment in metastatic urothelial cancer.

Editorial comment.

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.

Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.

Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer.

Emerging personalized approaches for the management of advanced urothelial carcinoma.

A prognostic model for metastatic renal-cell carcinoma.

Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.

Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.

Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.

Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.

Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group.

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches.

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

The impact of gender on outcomes in patients with metastatic urothelial carcinoma.

Metabolic complications with the use of mTOR inhibitors for cancer therapy.

Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

A new approach to second-line therapy for urothelial cancer?

Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.

Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.

Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.

Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.

Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.

Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.

Metastatic renal cancer: better never than late.

Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.

A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.

Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.

Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.

Adverse event reporting in cancer clinical trial publications.

Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.

Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.

Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.

New developments in urothelial cancer.

Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.

Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.

Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better?

A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer.

T2 muscle-invasive bladder cancer.

Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

Current approaches to the management of bladder cancer in older patients.

Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.

New drugs and treatment strategies in prostate cancer.

Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.

Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.

Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).

Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Rethinking cancer clinical trials for the future.

Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.

Adult cancer clinical trials that fail to complete: an epidemic?

Use of crowdsourcing for cancer clinical trial development.

Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?

Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.

Biomarkers for bladder cancer management: present and future.

Geographic accessibility to clinical trials for advanced cancer in the United States.

Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.

Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

How I treat bladder cancer in elderly patients.

Survival of patients with stage IV lung cancer with diabetes treated with metformin.

Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.

Kidney cancer: Systemic therapy--differentiating the achievable from the achieved.

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care.

A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.

Clinical trial awareness: Changes over time and sociodemographic disparities.

First-line treatment of metastatic disease: cisplatin-ineligible patients.

The landscape of precision cancer medicine clinical trials in the United States.

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.

Neoadjuvant chemotherapy in the management of muscle-invasive bladder cancer: bridging the gap between evidence and practice.

Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.